Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 2 Parkinson's papers of 411 | 0.85 |
| pathways Reactome | 4 pathways; mostly mitochondrial quality control | 1.00 |
No case: the score is under the bar. Receipt 9024
Sealed predictions
- CRTC1 in dopamine neurons, braak-0.15 (p 0.702) → -0.40 (p 0.292)receipt 9031
Swarm cases
receipt 9031: CRTC1 in dopamine neurons, braak
- power
- full sample -0.36 (p 0.140, n 18), 95% CI -0.71 to +0.13. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.34 (p 0.167, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.51 (p 0.031, n 18). not the mix.
- skeptic
- leave-one-out range -0.47 to -0.28, sign flips 0; without severely affected donors -0.36 (p 0.140, n 18). fragile.
- cell type
- strongest in microglia: -0.63 (p 0.0053, n 18) vs -0.36 in dopamine neurons. proposing microglia.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CRTC1 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up CRTC1 · microglia · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -1.00 p 3.8e-4 (needs p < 2.3e-4)
Receipts
loading the receipts